ClinicalTrials.gg
RecruitingNCT07632573Updated Jun 8, 2026

A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult

A Phase 1 interventional study of BDHK-2009 Tablets and Placebo in Ulcerative Colitis (UC), Ulcerative Colitis (Disorder) and Ulcerative Colitis Acute, sponsored by Benethera (Shaoxing) Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Benethera (Shaoxing) Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
89th of 136
68 · median 121
Started
2026
with 27 others
Phase 1
18 of 184
11 open now
Primary completion
2026-12
later than 34 of 95 live
Registered
170th of 184
by date

Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 89th largest by planned enrollment of the 136 interventional ones that give a count, is one of 28 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 34 of the 95 other live ones, and was the 170th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part 1) and multiple oral doses (Part 2) of BDHK-200 in healthy adult participants.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Ulcerative Colitis (Disorder)
  • Ulcerative Colitis Acute
  • IBD (Inflammatory Bowel Disease)
  • CD - Crohn's Disease

Keywords

  • Crohn's disease
  • Ulcerative Colitis
  • Inflammatory Bowel Disease
  • IBD
  • CD
  • UC
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 1. Participants who are able to communicate effectively with the investigator, understand and comply with the trial requirements, voluntarily participate in the trial, and understand and sign the form.

2. Healthy participants aged 18 to 55 years (inclusive), regardless of gender. 3. Weight ≥ 50 kg (for males) and ≥ 45 kg (for females), with a (BMI) of 18-26 kg/m².

4. At screening, physical examination, vital signs, 12-lead (ECG), and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, serological virology, thyroid function, etc.) results are either within normal limits or, if abnormal, not .

5. Women of (WOCBP) must have negative pregnancy test results at screening and baseline, and must not be pregnant, lactating, or planning pregnancy during the study period. WOCBP must agree to use acceptable measures during the treatment period and for at least 90 days after the last dose of the product (whichever is longer).

  1. WOCBP is defined as any female who has experienced menarche and has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not ;
  2. Non-childbearing potential females are defined as postmenopausal females and premenopausal females who have undergone sterilization surgery. Postmenopausal is defined as the absence of menstruation for ≥ 12 months without alternative medical intervention. Follicle-stimulating hormone (FSH) testing will be performed for subjects with uncertain status, and FSH > 40 mIU/mL can confirm menopause.

    6. Male participants with partners of childbearing potential are eligible for the study only if they agree to use acceptable contraceptive measures during the treatment period and for at least 90 days after the last dose of the investigational product, and agree not to donate sperm during this period. In addition, male participants with partners of childbearing potential must use condoms continuously until at least 90 days after the last dose of the investigational product (whichever is longer).

Exclusion criteria

Exclusion Criteria:

  • 1. As determined by the investigator, known or persistent psychiatric disorders requiring pharmacological intervention that may interfere with the participant's participation in the study, including but not limited to schizophrenia, bipolar disorder, or major depressive disorder.

    2. Participants with abnormalities in any disease or condition, including but not limited to metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurological, psychiatric, thyroid, or other disorders, as determined by the investigator to be unsuitable for participation in this study.

    3. Presence or suspected presence of active viral, bacterial, fungal, or parasitic infection.

    4. History of recurrent or chronic infections.

    5. Participants with acute illness within 2 weeks prior to screening; participants with clinically significant infections (e.g., upper respiratory tract infection, nasopharyngitis, urinary tract infection, etc.) within 3 months prior to screening; participants with evidence of any infection within 7 days prior to screening; participants with a history of herpes simplex infection or recurrent (>1 episode) herpes zoster or disseminated herpes zoster.

    6. History of epidemic meningococcal infection.

    7. History of splenectomy or functional asplenia.

    8. Participants with positive test results for surface antigen (HBsAg), antibody (anti-HCV), antibody (anti-HIV), or Treponema pallidum antibody.

    9. Participants with a history of active tuberculosis or evidence of active or latent tuberculosis infection at screening.

    10. Participants with a history of allergic tendencies, such as asthma, atopic dermatitis, chronic urticaria, or allergic rhinitis, or with allergies to two or more medications, foods, or pollens; participants with a history of to the drug or any of its components or to drugs with the same mechanism of action, or with clinically significant allergy history as determined by the investigator to be ineligible for enrollment.

    11. Participants who have participated in another interventional clinical study and received an interventional treatment (including investigational drugs and investigational medical devices) within 30 days prior to the first dose of the study drug, or within 5 half-lives of the study drug (whichever is longer).

    12. Participants with a history of drug abuse within 12 months prior to screening, or participants with positive urine drug screening results.

    13. Participants who have used any strong inducers or strong inhibitors of the hepatic metabolic enzyme within 14 days or 5 half-lives prior to administration of the investigational drug (whichever is longer).

    14. Participants who have used any prescription medications within 14 days prior to administration of the investigational drug, or any over-the-counter medications, herbal medicines, or dietary supplements within 7 days prior to administration of the investigational drug, unless the investigator determines that the medication is not clinically significant.

    15. Participants who have consumed any foods or beverages containing substances that may induce or inhibit hepatic metabolic enzymes (such as grapefruit, Seville orange, or star fruit, etc.) within 7 days prior to administration of the investigational drug, or who are unable to avoid consumption of foods or beverages containing caffeine within 48 hours prior to administration of the investigational drug and throughout the inpatient study period.

    16. Participants who consumed more than 14 units of alcohol per week within 1 month prior to screening (1 unit of alcohol is approximately equivalent to 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine), or who consumed any alcohol products within 24 hours prior to dosing, or who have positive alcohol screening test results.

    17. Heavy smokers or participants who smoked more than 5 cigarettes per day within 3 months prior to dosing, and who are unable to abstain from using more than 5 tobacco or nicotine-containing products (including nicotine patches) per week from screening through the end of the study.

    18. Participants who donated blood or experienced blood loss ≥ 200 mL within 1 month prior to screening or dosing, or who donated blood or experienced blood loss ≥ 400 mL within 3 months prior to dosing, or who have difficult venous access or are unable to tolerate blood sampling.

    19. At screening or baseline, 12-lead (ECG) findings showing clinically significant abnormalities, including but not limited to: > 450 ms, or other arrhythmias or morphological abnormalities as determined by the investigator that may increase participant risk or interfere with data interpretation.

    20. Participants with dysphagia or special dietary requirements who are unable to accept a standardized diet (e.g., severe food allergies).

    21. Participants who have undergone major surgical procedures within 3 months prior to screening or who are planning to undergo surgery during the trial period.

    22. Participants who have received vaccination within 8 weeks prior to screening, or who plan to receive vaccination during the study or within 8 weeks after administration of the study drug.

    23. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    BDHK-2009 Tablets

    SAD1-6: Participants will be randomized to receive either single dose of BDHK-2009 Tablets. SAD 4 will be double blinded cross-over period is to determine food effect and participants will receive BDHK2009 Tablets under fed conditions in the second period. MAD is repeat ascending dose sequential period. There will three cohortsof 8 healthy subjects. In each cohort subjects will be randomized to receive BDHK-2009 Tablets or Placebo in ratio 3:1. Subjects will receive BDHK-2009 Tablets QD.

    Drug: BDHK-2009 Tablets

  • Placebo comparator
    Placebo

    SAD1-6: Participants will be randomized to receive either single dose of Placebo. SAD 4 will be double blinded cross-over period is to determine food effect and participants will receive Placebo under fed conditions in the second period. MAD is repeat ascending dose sequential period. There will three cohortsof 8 healthy subjects. In each cohort subjects will be randomized to receive BDHK-2009 Tablets or Placebo in ratio 3:1. Subjects will receive Placebo QD.

    Drug: Placebo

Interventions

  • DrugBDHK-2009 Tablets

    Administration: Oral

  • DrugPlacebo

    Administration: Oral

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of a single dose/multiple doses of BDHK-2009 in healthy participants.

    Frequency of adverse events as assessed by the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 6.0 including clinical significant changes in safety laboratory, vital signs, 12-lead ECG, and physical examination

    Time frame: From enrollment to the end of treatment at week 4.

Secondary outcomes

  1. To evaluate the pharmacokinetics (PK) of a single dose/multiple doses of BDHK-2009 in healthy participants.

    Peak plasma Concentration (Cmax)

    Time frame: From enrollment to the end of treatment at week 4.

  2. To evaluate the pharmacokinetics (PK) of a single dose/multiple dose of BDHK-2009 in healthy participants.

    Area under the drug concentration-time curve (AUC)

    Time frame: From enrollment to the end of treatment at week 4.

  3. To evaluate the pharmacokinetics (PK) of a single dose/multiple dose of BDHK-2009 in healthy participants.

    Time to maximum observed concentration (Tmax)

    Time frame: From enrollment to the end of treatment at week 4.

  4. To evaluate the pharmacokinetics (PK) of a single dose/multiple doses of BDHK-2009 in healthy participants.

    Terminal half-life (t½)

    Time frame: From enrollment to the end of treatment at week 4.

  5. To evaluate the pharmacokinetics (PK) of a single dose/multiple doses of BDHK-2009 in healthy participants.

    Total plasma clearance of drug (CL/F)

    Time frame: From enrollment to the end of treatment at week 4.

  6. To evaluate the pharmacokinetics (PK) of a single dose/multiple doses of BDHK-2009 in healthy participants.

    Volume of distribution after oral administration (Vz/F)

    Time frame: From enrollment to the end of treatment at week 4.

  7. To evaluate the pharmacodynamics (PD) of a single dose/multiple doses of BDHK-2009 in healthy participants.

    Change from baseline of cytokines levels

    Time frame: From enrollment to the end of treatment at week 4

  8. To evaluate the effect of a high fat meal on the pharmacokinetics (PK) of a single dose of BDHK-2009 in healthy participants.

    Peak plasma Concentration (Cmax)

    Time frame: From enrollment to the end of treatment at week 4.

  9. To evaluate the effect of a high fat meal on the pharmacokinetics (PK) of a single dose of BDHK-2009 in healthy participants.

    Area under the drug concentration-time curve (AUC)

    Time frame: From enrollment to the end of treatment at week 4.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's planned 7 months is below that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 8, 2026
StartActual
May 18, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 28, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07632573
Lead sponsor
Benethera (Shaoxing) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
May 18, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Shuang Zhang
Contact
zhangshuang@benethera.com
+86-010-82146616
Jinliang Chen
principal investigator · Zhejiang Xiaoshan hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion